While commonly found and successfully targeted in non-small cell lung cancer, ALK alterations have been recently reported in a subset of NETs, including patients with pulmonary NETs (5.2%), with successful treatment with crizotinib, a selective ALK inhibitor [78,79]. Here, ALK is linked to non-small cell lung carcinoma.